EXT1 and post-transplant lymphoproliferative disease: Our novel study of TTV kinetics post-HSCT demonstrated the highest levels of TTV in immunocompromised PTLD patients and the lowest in healthy donors, suggesting that TTV levels increase with a reduction in the host’s immunocompetence.